Affiliation: University of Miami
- Breast cancer and human immunodeficiency virus: a report of 20 casesJ Hurley
Division of Hematology Oncology, University of Miami and the Breast Health Center, Jackson Memorial Hospital, Miami, FL, USA
Clin Breast Cancer 2:215-20; discussion 221. 2001..Breast cancer in the HIV-positive population is similar to that seen in seronegative women. Most of the patients that are long-term survivors were treated with surgery and tamoxifen. The benefits of adjuvant chemotherapy are not clear...
- Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancerJudith Hurley
Sylvester Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
J Clin Oncol 24:1831-8. 2006..To evaluate the efficacy and safety of docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2 (HER2) -positive, locally advanced breast cancer (LABC)...
- Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancerJudith Hurley
Sylvester Cancer Center, University of Miami, 1475 NW 12th Ave, D8 4, FL 33136, USA
Clin Breast Cancer 5:447-54. 2005..The most common adverse nonhematologic events were fatigue (84% of patients) and alopecia (84%), which were usually grade 1/2. Weekly docetaxel/carboplatin appears to be active and feasible as PST in patients with large breast tumors...
- Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapyJ L Wright
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
Breast 21:276-83. 2012..We assessed racial differences in progression-free survival (PFS) and overall survival (OS) in relation to subtype in uniformly treated stage II-III breast cancer patients...
- Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancerA J Montero
Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Avenue, Suite 3510 D8 4, Miami, FL 33136, USA
Breast Cancer Res Treat 132:215-23. 2012..Patients with lower levels of circulating MDSCs at baseline and on the last cycle of chemotherapy had significantly higher probability of a pCR (P = 0.02). Further evaluation of NOV-002 in a randomized study is warranted...
- Breast cancer patients have improved immune and neuroendocrine functions following massage therapyMaria Hernandez-Reif
Touch Research Institutes, University of Miami School of Medicine, 1601 NW 12th Avenue, Room 7037, Miami, FL 33136, USA
J Psychosom Res 57:45-52. 2004....
- Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanomaLynn Feun
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA
Cancer Invest 23:3-8. 2005..Toxicity was generally well tolerated and included myelosuppression and fatigue. This regimen is feasible and generally tolerable and has produced an antitumor response rate comparable with inpatient biochemotherapy regimens...
- Natural killer cells and lymphocytes increase in women with breast cancer following massage therapyMaria Hernandez-Reif
Touch Research Institutes, University of Miami School of Medicine, Miami, FL 33101, USA
Int J Neurosci 115:495-510. 2005..These findings highlight the benefit of these complementary therapies, most particularly massage therapy, for women with breast cancer...
- Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanomaLynn G Feun
Sylvester Comprehensive Cancer Center, University of Miami, 1475 N.W. 12th Avenue, Miami, FL 33136, USA
Cancer Invest 20:357-61. 2002..Toxicity was generally tolerable and included mainly neurotoxicity from Paclitaxel. At the doses and schedule used, the combination of Paclitaxel and DTIC did not appear to increase the response rate compared to each agent used singly...
- Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancerChristopher Lobo
Florida Cancer Specialists and Research Institute, Gainesville, FL, USA
Breast Cancer Res Treat 123:427-35. 2010..First-line therapy with nab-P, B, and G demonstrated a median PFS of 10.4 months and a 75.9% ORR with acceptable toxicity; this novel combination warrants investigation in a randomized study...
- A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancerOrlando Silva
Division of Hematology and Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
Clin Breast Cancer 8:162-7. 2008..A schedule with split, low-dose docetaxel in combination with low-dose capecitabine could improve the therapeutic index of this regimen without compromising its clinical activity...
- Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiationJ E Panoff
Department of Radiation Oncology, University of Miami School of Medicine, Miami, FL 33136, USA
Breast Cancer Res Treat 128:899-906. 2011..In the era of HER-2 targeted therapy, tumors that are HER-2 over expressing and are treated with trastuzumab have a very low rate of LRR. ER negative, PR negative, and triple negative status are associated with increased risk of LRR...
- A comprehensive evaluation of outcomes for inflammatory breast cancerRelin Yang
DeWitt Daughtry Family Department of Surgery, Division of Surgical Oncology, Sylvester Comprehensive Cancer Center, Alan Livingstone Chair in Surgical Oncology, University of Miami Miller School of Medicine, 3550 Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave, Miami, FL 33136, USA
Breast Cancer Res Treat 117:631-41. 2009..We sought to determine the effects of race, socioeconomic status and treatment on outcomes for women with IBC. Study design The Florida cancer registry, inpatient and ambulatory data were queried for patients diagnosed from 1998 to 2002...
- African-American and low-socioeconomic status patients have a worse prognosis for invasive ductal and lobular breast carcinoma: do screening criteria need to change?Relin Yang
DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
J Am Coll Surg 208:853-68; discussion 869-70. 2009..Determine the effect of race, socioeconomic status (SES) and other demographic variables on outcomes of patients with invasive ductal and lobular breast cancer...
- Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancersYoung J Lee
Harbor Hospital, Baltimore, MD, USA
Clin Breast Cancer 5:371-6. 2004..The results of this study suggest that the docetaxel/cisplatin combination can be an effective and well-tolerated induction treatment of LABC, even in very large mostly HER2-nonoverexpressing tumors...
- Pain education for underserved minority cancer patients: a randomized controlled trialKaren O Anderson
Department of Symptom Research, The University of Texas M D Anderson Cancer Center, 1100 Holcombe Blvd, Box 221, Houston, TX 77030, USA
J Clin Oncol 22:4918-25. 2004..Previous studies found that African American and Hispanic cancer patients are at risk for undertreatment of pain. We evaluated the efficacy of a pain education intervention for underserved minority patients...